The “positive” results announced yesterday in the Zepzelca trial for lung cancer not only increased PharmaMar shares by 32.69%. The analytics company has made the first improvements in their biopharmaceutical assessment by including advances in one of their flagship drugs.
One day PharmaMar has skyrocketed in the rankings of the best values on the Spanish stock market. At yesterday's close, his shares in 2024 were revaluation 63%fifth largest in the entire Sustainable Market. Half of this profit is
To continue reading, use Premium
Try it for €1 the first month
and enjoy unlimited access to all Expansión web content
Or register with your Google account in two clicks